Biomerieux India Private Limited Vs Commissioner of Customs (Audit) (CESTAT Chennai)
Conclusion: ELFA-based VIDAS diagnostic kits were eligible for the customs exemption available to ELISA kits under Notification No. 50/2017-Cus. It further held that the dispute was interpretational, the extended limitation period was wrongly invoked, and the consequential demand of duty, interest, confiscation, redemption fine, and penalties was liable to be set aside.
Held: Assessee-company imported sixteen varieties of VIDAS diagnostic kits based on Enzyme-Linked Fluorescent Assay (ELFA) technology and claimed exemption from Basic Customs Duty and concessional IGST under Notification No. 50/2017-Cus., treating the products as ELISA kits. Revenue denied the exemption on the ground that the notification specifically covered ELISA kits and not ELFA kits, alleging deliberate misdeclaration in the Bills of Entry. A differential duty demand of ₹68.20 crores, along with interest, confiscation, redemption fine, and penalties, was confirmed by the adjudicating authority, which also invoked the extended limitation period under Section 28(4) of the Customs Act. Assessee-company contended that ELFA was merely a technologically advanced form of ELISA, both operating on the same enzyme-linked immunoassay principle, with the only distinction being the method of signal detection. It relied upon scientific literature, expert opinions of the CDSCO and National Institute of Biologicals (NIB), earlier customs assessments granting identical exemptions, and judicial precedents supporting purposive interpretation of beneficial exemption notifications. Assessee further argued that the dispute was interpretational in nature, all material facts were disclosed, and therefore extended limitation, interest, confiscation, redemption fine, and penalties were inapplicable. Revenue contended that exemption notifications require strict interpretation and that only products expressly described as ELISA kits qualified for exemption. It argued that ELFA represented a distinct diagnostic technology, that the importer knowingly misdeclared the goods as ELISA kits despite supplier invoices describing them only as VIDAS test kits, and that such misdeclaration justified denial of exemption, invocation of the extended period, confiscation, redemption fine, and penalties. Tribunal held that ELFA was not a distinct scientific methodology but a technologically advanced application of the broader ELISA principle, differing only in fluorescence-based detection while retaining the same underlying antigen-antibody immunoassay mechanism. Expert opinions of CDSCO and NIB, supported by authoritative scientific literature, established that ELFA and ELISA were fundamentally the same for diagnostic purposes. Beneficial exemption notifications concerning healthcare and diagnostic products must be interpreted purposively to accommodate technological advancements rather than frozen to outdated scientific understanding. Tribunal held that the Revenue could not disregard expert regulatory opinions or deny exemption merely because detection technology had evolved. Since the dispute was one of interpretation and all relevant facts were disclosed, the ingredients of wilful suppression or misstatement necessary for invoking the extended limitation under Section 28(4) were absent. Consequently, the demand of differential duty, interest, confiscation, redemption fine, and penalties was unsustainable.
